Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.63 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.63 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 4/20 | 0.51 |
| ▸ | GCGR | P47871 | 4/20 | 0.51 |
| ▸ | GIPR | P48546 | 1/20 | 0.51 |
| ▸ | NMBR | P28336 | 1/20 | 0.51 |
| ▸ | GRPR | P30550 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
| ▸ | MC1R | Q01726 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513768 | 0.98 | CTSL (0.62) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29677323 | 0.95 | CTSL (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30821694 | 0.94 | CTSL (0.69) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30574265 | 0.92 | C5AR1 (0.56) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL31694509 | 0.88 | C5AR1 (0.73) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29754594 | 0.87 | C5AR1 (0.70) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29389916 | 0.87 | C5AR1 (0.68) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30750900 | 0.87 | C5AR1 (0.64) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29387436 | 0.87 | C5AR1 (0.68) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL31040596 | 0.86 | CTSL (0.59) | CTSLCTSSCTSKCTSHC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180811-B1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | CELL COPEDIA GMBH (DE) | 2025-04-09 | — | — | EP | claimed |
| US-20250019723-A1 | METHODS, KITS, AGENTS AND APPARATUSES FOR TRANSDUCTION | JUNO THERAPEUTICS GMBH (DE) | 2025-01-16 | — | — | US | claimed |
| US-12129477-B2 | Methods, kits, agents and apparatuses for transduction | JUNO THERAPEUTICS GMBH (DE) | 2024-10-29 | — | — | US | claimed |
| US-11965882-B2 | Methods of isolating a biological entity | Cell.Copedia GmbH (DE) | 2024-04-23 | — | — | US | claimed |
| CN-109071616-B | Streptavidin muteins and methods of use thereof | IBA股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2023147510-A1 | CHROMATOGRAPHY ARRAYS AND RELATED METHODS AND KITS | JUNO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| US-20230190952-A1 | CELL SURFACE CONJUGATES AND RELATED CELL COMPOSITIONS AND METHODS | JUNO THERAPEUTICS GMBH (DE) | 2023-06-22 | — | — | US | claimed |
| US-20230140446-A1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | Cell.Copedia GmbH (DE) | 2023-05-04 | — | — | US | claimed |
| US-11517627-B2 | Cell surface conjugates and related cell compositions and methods | JUNO THERAPEUTICS GMBH (DE) | 2022-12-06 | — | — | US | claimed |
| EP-4004545-B1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | CELL COPEDIA GMBH (DE) | 2022-11-02 | — | — | EP | claimed |
| US-11466253-B2 | Methods for culturing cells and kits and apparatus for same | JUNO THERAPEUTICS GMBH (DE) | 2022-10-11 | — | — | US | claimed |
| US-20220243223-A1 | METHODS, KITS, AGENTS AND APPARATUSES FOR TRANSDUCTION | JUNO THERAPEUTICS GMBH (DE) | 2022-08-04 | — | — | US | claimed |
| US-20220204935-A1 | MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-06-30 | — | — | US | claimed |
| US-20220169723-A1 | TAGGED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | FRED HUTCHINSON CANCER CENTER | 2022-06-02 | — | — | US | claimed |
| EP-3995142-A2 | MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF | Fred Hutchinson Cancer Research Center (US) | 2022-05-11 | — | — | EP | claimed |
| US-20260139027-A1 | PROCESS FOR PRODUCING A COMPOSITION OF ENGINEERED T CELLS | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4737561-A2 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | Juno Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-114207136-A | Automated T cell culture | 朱诺治疗学股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220056083-A1 | STREPTAVIDIN MUTEINS AND METHODS OF USING THEM | IBA LIFESCIENCES GMBH (GI) | 2022-02-24 | — | — | US | disclosed |
| US-11248238-B2 | Methods, kits, agents and apparatuses for transduction | JUNO THERAPEUTICS GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139027-A1 | PROCESS FOR PRODUCING A COMPOSITION OF ENGINEERED T CELLS | CD4, ICOS, IL2 | CTSL 191/4885CTSS 406/4885CTSK 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.